Cabozantinib in advanced renal cell carcinoma: A phase II, open‐label, single‐arm study of Japanese patients

Abstract

The results showed that findings from METEOR can be extrapolated, and that cabozantinib 60 mg/day is a viable treatment option in Japanese patients with advanced renal cell carcinoma who had progressed after prior tyrosine kinase inhibitor therapy.